Literature DB >> 16061753

Response of atrial fibrillation to pulmonary vein antrum isolation is directly related to resumption and delay of pulmonary vein conduction.

Atul Verma1, Fethi Kilicaslan, Ennio Pisano, Nassir F Marrouche, Raffaele Fanelli, Johannes Brachmann, Jens Geunther, Domenico Potenza, David O Martin, Jennifer Cummings, J David Burkhardt, Walid Saliba, Robert A Schweikert, Andrea Natale.   

Abstract

BACKGROUND: The role of pulmonary vein (PV) isolation in ablative treatment of atrial fibrillation (AF) has been debated in conflicting reports. We sought to compare PV conduction in patients who had no AF recurrence (group I), patients who could maintain sinus rhythm on antiarrhythmic medication (group II), and patients who had recurrent AF despite antiarrhythmic medication (group III) after PV antrum isolation (PVAI). METHODS AND
RESULTS: PV conduction was examined in consecutive patients undergoing second PVAI for AF recurrence. We also recruited some patients cured of AF to undergo a repeat, limited electrophysiological study at >3 months after PVAI. All patients underwent PVAI with an intracardiac echocardiography (ICE)-guided approach with complete isolation of all 4 PV antra (PVA). The number of PVs with recurrent conduction and the shortest atrial to PV (A-PV) conduction delay was measured with the use of consistent Lasso positions defined by ICE. Late AF recurrence was defined as AF >2 months after PVAI with the patient off medications. Patients in groups I (n=26), II (n=37), and III (n=44) did not differ at baseline (38% permanent AF; ejection fraction 53+/-6%). Recurrence of PV-left atrial (LA) conduction was seen in 1.7+/-0.8 and 2.2+/-0.8 PVAs for groups II and III but only in 0.2+/-0.4 for group I (P=0.02). In patients with recurrent PV-LA conduction, the A-PV delay increased from the first to second procedure by 69+/-47% for group III, 267+/-110% for group II, and 473+/-71% for group I (P<0.001). When pacing was at a faster rate, A-PV block developed in all 5 of the group I patients with recurrent PV-LA conduction.
CONCLUSIONS: The majority of patients with drug-free cure show no PV-LA conduction recurrence. Substantial A-PV delay is seen in patients able to maintain sinus rhythm on antiarrhythmic medication or cured of AF compared with patients who fail PVAI.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16061753     DOI: 10.1161/CIRCULATIONAHA.104.533190

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  96 in total

1.  Efficacy of pulmonary vein isolation with a novel hot balloon ablation catheter.

Authors:  Rudolph F Evonich; David M Nori; David E Haines
Journal:  J Interv Card Electrophysiol       Date:  2012-01-08       Impact factor: 1.900

2.  The importance of catheter stability evaluated by Visitag(TM) during pulmonary vein isolation.

Authors:  Ryudo Fujiwara; Kimitake Imamura; Yoichi Kijima; Tomoya Masano; Ryoji Nagoshi; Amane Kohzuki; Hiroyuki Shibata; Yoshiro Tsukiyama; Ryo Takeshige; Kenichi Yanaka; Shinsuke Nakano; Yusuke Fukuyama; Junya Shite
Journal:  J Interv Card Electrophysiol       Date:  2016-01-19       Impact factor: 1.900

3.  Evaluation of left atrial lesions after initial and repeat atrial fibrillation ablation: lessons learned from delayed-enhancement MRI in repeat ablation procedures.

Authors:  Troy J Badger; Marcos Daccarett; Nazem W Akoum; Yaw A Adjei-Poku; Nathan S Burgon; Thomas S Haslam; Saul Kalvaitis; Suman Kuppahally; Gaston Vergara; Lori McMullen; Paul A Anderson; Eugene Kholmovski; Rob S MacLeod; Nassir F Marrouche
Journal:  Circ Arrhythm Electrophysiol       Date:  2010-03-24

4.  Can we ablate permanent atrial fibrillation?

Authors:  G Haywood
Journal:  Heart       Date:  2005-11-24       Impact factor: 5.994

5.  Clinical utility of automated ablation lesion tagging based on catheter stability information (VisiTag Module of the CARTO 3 System) with contact force-time integral during pulmonary vein isolation for atrial fibrillation.

Authors:  Yasuo Okumura; Ichiro Watanabe; Kazuki Iso; Koichi Nagashima; Kazumasa Sonoda; Naoko Sasaki; Rikitake Kogawa; Keiko Takahashi; Kimie Ohkubo; Toshiko Nakai; Shiro Nakahara; Yuuichi Hori; Atsushi Hirayama
Journal:  J Interv Card Electrophysiol       Date:  2016-06-09       Impact factor: 1.900

6.  Randomized comparison of contact force-guided versus conventional circumferential pulmonary vein isolation of atrial fibrillation: prevalence, characteristics, and predictors of electrical reconnections and clinical outcomes.

Authors:  Kohki Nakamura; Shigeto Naito; Takehito Sasaki; Masahiro Nakano; Kentaro Minami; Yosuke Nakatani; Kentaro Ikeda; Eiji Yamashita; Koji Kumagai; Nobusada Funabashi; Shigeru Oshima
Journal:  J Interv Card Electrophysiol       Date:  2015-09-19       Impact factor: 1.900

7.  Pulmonary vein re-isolation for atrial fibrillation using duty-cycled phased radiofrequency ablation: safety and efficacy of a primary 2:1 bipolar/unipolar ablation mode.

Authors:  Marcus Wieczorek; Reinhard Hoeltgen; Shahram Tajtaraghi; Wolfgang Lawrenz; Michael Lukat
Journal:  J Interv Card Electrophysiol       Date:  2012-10-25       Impact factor: 1.900

8.  Which is the best catheter to perform atrial fibrillation ablation? A comparison between standard ThermoCool, SmartTouch, and Surround Flow catheters.

Authors:  Luigi Sciarra; Paolo Golia; Andrea Natalizia; Ermenegildo De Ruvo; Serena Dottori; Antonio Scarà; Alessio Borrelli; Lucia De Luca; Marco Rebecchi; Alessandro Fagagnini; Alberto Bandini; Fabrizio Guarracini; Marcello Galvani; Leonardo Calò
Journal:  J Interv Card Electrophysiol       Date:  2014-02-21       Impact factor: 1.900

9.  The clinical efficacy of left atrial appendage isolation caused by extensive left atrial anterior wall ablation in patients with atrial fibrillation.

Authors:  Hwan-Cheol Park; DaeIn Lee; Jaemin Shim; Jong-Il Choi; Young-Hoon Kim
Journal:  J Interv Card Electrophysiol       Date:  2016-03-07       Impact factor: 1.900

10.  Novel balloon catheter device with pacing, ablating, electroporation, and drug-eluting capabilities for atrial fibrillation treatment--preliminary efficacy and safety studies in a canine model.

Authors:  Christopher V DeSimone; Elisa Ebrille; Faisal F Syed; Susan B Mikell; Scott H Suddendorf; Douglas Wahnschaffe; Dorothy J Ladewig; Emily J Gilles; Andrew J Danielsen; David R Holmes; Samuel J Asirvatham
Journal:  Transl Res       Date:  2014-07-16       Impact factor: 7.012

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.